Open AccessDevelopment of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo
Author(s) -
Denise Garcia,
Patrick Nasarre,
Ingrid Vivas Bonilla,
Eleanor Hilliard,
Yuri K. Peterson,
Laura Spruill,
Ann-Marie Broome,
Elizabeth G. Hill,
Jason T. Yustein,
Shikhar Mehrotra,
Nancy Klauber-DeMore
Publication year - 2019
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-07800-2
Subject(s) - medicine , in vivo , cancer research , monoclonal antibody , antibody , angiosarcoma , apoptosis , angiogenesis , breast cancer , cancer , pathology , immunology , biology , biochemistry , microbiology and biotechnology
We previously reported that secreted frizzled-related protein-2 (SFRP2) is expressed in a variety of tumors, including sarcoma and breast carcinoma, and stimulates angiogenesis and inhibits tumor apoptosis. Therefore, we hypothesized that a humanized SFRP2 monoclonal antibody (hSFRP2 mAb) would inhibit tumor growth.